Literature DB >> 25806175

Dulanermin in cancer therapy: still much to do.

Cristina Quintavalle1, Gerolama Condorelli2.   

Abstract

Entities:  

Year:  2012        PMID： 25806175      PMCID： PMC4367577          DOI： 10.3978/j.issn.2218-6751.2012.02.03

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  15 in total

Review 1.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily.

Authors:  Avi Ashkenazi
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

2.  Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.

Authors:  Jean-Charles Soria; Zsuzsanna Márk; Petr Zatloukal; Barna Szima; István Albert; Erzsébet Juhász; Jean-Louis Pujol; Jerzy Kozielski; Nigel Baker; Dominic Smethurst; Yong-jiang Hei; Avi Ashkenazi; Howard Stern; Lukas Amler; Yang Pan; Fiona Blackhall
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

Review 3.  MicroRNAs as regulators of death receptors signaling.

Authors:  M Garofalo; G L Condorelli; C M Croce; G Condorelli
Journal:  Cell Death Differ       Date:  2009-07-31       Impact factor: 15.828

4.  Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.

Authors:  Jean-Charles Soria; Egbert Smit; David Khayat; Benjamin Besse; Xinqun Yang; Cheng-Pang Hsu; David Reese; Jeffrey Wiezorek; Fiona Blackhall
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

5.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Authors:  Michela Garofalo; Gianpiero Di Leva; Giulia Romano; Gerard Nuovo; Sung-Suk Suh; Apollinaire Ngankeu; Cristian Taccioli; Flavia Pichiorri; Hansjuerg Alder; Paola Secchiero; Pierluigi Gasparini; Arianna Gonelli; Stefan Costinean; Mario Acunzo; Gerolama Condorelli; Carlo Maria Croce
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

Review 6.  Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.

Authors:  Avi Ashkenazi
Journal:  Nat Rev Drug Discov       Date:  2008-11-07       Impact factor: 84.694

Review 7.  TRAIL: a multifunctional cytokine.

Authors:  Uta Schaefer; Oksana Voloshanenko; Daniela Willen; Henning Walczak
Journal:  Front Biosci       Date:  2007-05-01

Review 8.  TRAIL and other TRAIL receptor agonists as novel cancer therapeutics.

Authors:  Christina Falschlehner; Tom M Ganten; Ronald Koschny; Uta Schaefer; Henning Walczak
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

9.  Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours.

Authors:  Y Pan; R Xu; M Peach; C-P Huang; D Branstetter; W Novotny; R S Herbst; S G Eckhardt; P M Holland
Journal:  Br J Cancer       Date:  2011-10-27       Impact factor: 7.640

10.  PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer.

Authors:  Ciro Zanca; Michela Garofalo; Cristina Quintavalle; Giulia Romano; Mario Acunzo; Pia Ragno; Nunzia Montuori; Mariarosaria Incoronato; Luigi Tornillo; Daniel Baumhoer; Carlo Briguori; Luigi Terracciano; Gerolama Condorelli
Journal:  J Cell Mol Med       Date:  2008-02-15       Impact factor: 5.310
View more
  8 in total

1.  Expression and significance of miRNA-21 and BTG2 in lung cancer.

Authors:  Qing Sun; Meng Hang; Xuedan Guo; Wenlong Shao; Guangqiao Zeng
Journal:  Tumour Biol       Date:  2013-07-16

Review 2.  Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer.

Authors:  Kelly Xue Jing Jong; Elsa Haniffah Mejia Mohamed; Zaridatul Aini Ibrahim
Journal:  Apoptosis       Date:  2022-10-07       Impact factor: 5.561

3.  Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells.

Authors:  Weiguo Cao; Rong Fan; Lifu Wang; Shidan Cheng; Hao Li; Jinsong Jiang; Mei Geng; Yening Jin; Yunlin Wu
Journal:  Tumour Biol       Date:  2012-12-22

4.  Clustering of Death Receptor for Apoptosis Using Nanoscale Patterns of Peptides.

Authors:  Yang Wang; Igor Baars; Ferenc Fördös; Björn Högberg
Journal:  ACS Nano       Date:  2021-05-21       Impact factor: 18.027

Review 5.  Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.

Authors:  Anna-Laura Kretz; Silvia von Karstedt; Andreas Hillenbrand; Doris Henne-Bruns; Uwe Knippschild; Anna Trauzold; Johannes Lemke
Journal:  Cancers (Basel)       Date:  2018-03-18       Impact factor: 6.639

Review 6.  The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials.

Authors:  Martin Snajdauf; Klara Havlova; Jiri Vachtenheim; Andrej Ozaniak; Robert Lischke; Jirina Bartunkova; Daniel Smrz; Zuzana Strizova
Journal:  Front Mol Biosci       Date:  2021-03-10

7.  MicroRNA‑21 regulates the expression of BTG2 in HepG2 liver cancer cells.

Authors:  Bijing Mao; He Xiao; Zhimin Zhang; Dong Wang; Ge Wang
Journal:  Mol Med Rep       Date:  2015-07-07       Impact factor: 2.952

8.  Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy.

Authors:  Jae Do Yoo; Sang Mun Bae; Junyoung Seo; In Seon Jeon; Sri Murugan Poongkavithai Vadevoo; Sang-Yeob Kim; In-San Kim; Byungheon Lee; Soyoun Kim
Journal:  Sci Rep       Date:  2020-11-17       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.